Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2010 /
Pertuzumab and trastuzumab combo improves efficacy for HER2-positive breast cancer

8th - 12th Dec 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.01.11
Views: 4658
Rating:

Prof Luca Gianni - Istituto Nazionale Tumori, Milan, Italy

Talking to ecancertv at the 2010 San Antonio Breast Cancer Symposium, Prof Gianni explains how adding pertuzumab to trastuzumab and docetaxel eradicated tumours. Some tumours were eradicated without chemotherapy. The findings establish that the addition of pertuzumab to trastuzumab and the chemotherapy drug docetaxel has an impressive rate of tumour eradication (46 %), which is 50 % more than achieved with docetaxel and trastuzumab, the standard therapy. NeoSphere is a randomized trial that tested the efficacy of the new HER2-directed monoclonal antibody pertuzumab in combination with trastuzumab with or without chemotherapy. The trial included 417 women; all participants received four cycles of therapy before they underwent surgery, or as neoadjuvant therapy. The results showed that combining pertuzumab with trastuzumab might offer improved efficacy to women with early HER2-positive breast cancer, according to Gianni. Additionally, a small percentage of tumors could be treated and eventually cured without chemotherapy. The most important result of the study is that a relatively small neoadjuvant trial of short duration can rapidly provide data that better outline the value of different new strategies and shape the approach to further and much larger adjuvant studies.

Categories:

Breast · Drug development · SABCS 2010

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation